earnings
confidence high
sentiment positive
materiality 0.80
Gilead Q3 GAAP EPS $2.05, revenue $7.4B; Biktarvy record $2.3B; raises FY guidance; redeems $1B notes
GILEAD SCIENCES, INC.
2021-Q3 EPS reported
$4.63
revenue$20,061,000,000
- GAAP diluted EPS $2.05 vs $0.29 YoY; non-GAAP diluted EPS $2.65 vs $2.11 YoY.
- Total Q3 revenue $7.4B (+13% YoY); product sales ex-Veklury $5.4B (-3% YoY).
- Biktarvy sales record $2.3B (+20% YoY); Veklury sales $1.9B.
- FY 2021 guidance raised: total product sales $26.0-26.3B; non-GAAP EPS $7.90-8.10.
- Called $1B of 2023 notes (Floating Rate and 0.750% Senior Notes) for redemption on Nov 8, 2021.